The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
Recruiting
Observational Study
Arteriovenous Malformation of Central Nervous System
Aneurysm, Ruptured
Aneurysmatic Subarachnoid Haemorrhage
Aneurysm Cerebral
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT
2. No history of stroke, Marfan syndrome, polycystic kidney disease
Exclusion Criteria:
1. pAVM without flow-related aneurysms
2. Absence of clinical data
Contacts